Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Multicenter, Open-Label, Phase 3 Study of Acalabrutinib (ACP-196) Versus Investigator's Choice of Either Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in Subjects with Relapsed or Refractory Chronic Lymphocytic Leukemia

Next Previous
Trial Profile

A Randomized, Multicenter, Open-Label, Phase 3 Study of Acalabrutinib (ACP-196) Versus Investigator's Choice of Either Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in Subjects with Relapsed or Refractory Chronic Lymphocytic Leukemia

Status: Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 29 Nov 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Acalabrutinib (Primary) ; Bendamustine; Idelalisib; Rituximab
  • Indications Chronic lymphocytic leukaemia
  • Focus Registrational; Therapeutic Use
  • Acronyms ASCEND
  • Sponsors Acerta Pharma

Most Recent Events

  • 29 Aug 2024 Planned End Date changed from 6 Sep 2027 to 1 Oct 2027.
  • 24 May 2024 According to a BeiGene Media Release, the presentation of a network meta-analysis evaluating the relative efficacy of available treatments for patients with high-risk relapsed/refractory (R/R) CLL from clinical trials ALPINE, ELEVATE-RR and ASCEND will be presented at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, May 31 - June 4, 2024.
  • 24 May 2024 Results of network meta-analysis using data from clinical trials ALPINE, ELEVATE-RR and ASCEND presented in the BeiGene Media Release.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top